Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Summarize this article with:
This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article contentInitiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platformSign In or Create an AccountEmail AddressContinueor View more offersArticle contentSAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) — Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the first patient has been dosed in the Phase 1/2 clinical trial (NCT07300241) evaluating NEO-811, a novel investigational molecular glue degrader, in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC).Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentArticle content“Dosing the first patient in our Phase 1/2 trial of NEO-811 in renal cell carcinoma marks a pivotal inflection point for Neomorph, representing the first clinical evaluation of an asset from our internally developed pipeline,” said Phil Chamberlain, DPhil., Co-Founder, President, and Chief Executive Officer of Neomorph. “As we advance in the clinic, we look forward to generating data that will inform the continued development of NEO-811 and further validate the potential of our platform to deliver differentiated medicines for patients with significant unmet need.”Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentThe Phase 1/2 NEO-811-101 trial is a first-in-human, open-label study consisting of a single agent dose-escalation phase followed by dose expansion cohorts. The study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of NEO-811 in patients with locally advanced or metastatic non-resectable ccRCC.Article content“We are pleased to have the first patient dosed in the Phase 1/2 study of NEO-811,” said Toni Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School, and chair of the study steering committee. “NEO-811 is a novel, potent, cereblon-dependent, and selective molecular glue degrader designed to fully block a key signaling pathway in clear cell renal cell cancer. The unique mechanism of action of NEO-811 is quite promising and could offer a new treatment option for patients.”Article contentArticle contentAbout NEO-811NEO-811 is an investigational molecular glue degrader designed to induce targeted degradation of a key disease-driving protein and fully block a central signaling pathway implicated in ccRCC. By leveraging a differentiated degradation mechanism, NEO-811 has the potential to address underlying tumor biology that remains inadequately treated with current standards of care. NEO-811 is currently being evaluated as a monotherapy in a first-in-human Phase 1/2 clinical trial in patients with locally advanced or metastatic non-resectable ccRCC.Article contentAbout NeomorphNeomorph is a biotechnology company pioneering the discovery and development of molecular glue degraders to unlock new therapeutic possibilities across serious diseases. By engineering neomorphic protein surfaces, Neomorph enables precision targeted protein degradation of disease drivers that have historically been considered undruggable.Article contentAs a leader in molecular glue technology, Neomorph has created the world’s largest proprietary molecular glue target space, spanning multiple novel degrons across an expansive portfolio of E3 ubiquitin ligases. The company was founded in 2020 and is venture-backed by Deerfield Management Company. For more information, visit www.neomorph.com and follow us on LinkedIn.Article contentContactsInvestor Contact: inquiries@neomorph.comMedia Contact: media@neomorph.comArticle contentArticle contentArticle contentArticle contentArticle contentArticle contentTrending Despite 'elbows up,' Canada on track to be net lender to U.S. for ninth straight year Economy Avoid these TFSA and RRSP mistakes to keep the CRA off your back Personal Finance U.S. startup incubator's decision to shun Canada brings investors to the country's defence Innovation Subscriber only. In Canadian real estate's longest winter, buyers hold the power as sellers face reality Subscriber only Real Estate A tidal wave of business exits is coming, with $300 billion in revenue up for grabs, says BDC Economy Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. Despite 'elbows up,' Canada on track to be net lender to U.S. for ninth straight year Economy Avoid these TFSA and RRSP mistakes to keep the CRA off your back Personal Finance U.S. startup incubator's decision to shun Canada brings investors to the country's defence Innovation Subscriber only. In Canadian real estate's longest winter, buyers hold the power as sellers face reality Subscriber only Real Estate A tidal wave of business exits is coming, with $300 billion in revenue up for grabs, says BDC Economy